BRAF and non-small cell lung carcinoma: However, as in melanoma, drug combinations appear to yield increased efficacy in V600E BRAF-mutant NSCLC, with dabrafenib plus trametinib, an MEK inhibitor, showing an impressive RR of 63% and a PFS of 9.7 months [67].